Application of gene targeting by Small Fragment Homologous Replacement (SFHR) to human Cystic Fibrosis stem-like and differentiated cellular systems

Anno
2019
Proponente Marco Lucarelli - Professore Associato
Sottosettore ERC del proponente del progetto
LS2_1
Componenti gruppo di ricerca
Componente Categoria
Giampiero Ferraguti Componenti strutturati del gruppo di ricerca
Sabina Maria Bruno Dottorando/Assegnista/Specializzando componente non strutturato del gruppo di ricerca
Andrea Fuso Componenti strutturati del gruppo di ricerca
Componente Qualifica Struttura Categoria
Claudia Codazzo Contrattista Medicina Clinica Altro personale aggregato Sapienza o esterni, titolari di borse di studio di ricerca
Giancarlo Testino Tecnico di laboratorio Medicina Traslazionale e di Precisione Altro personale aggregato Sapienza o esterni, titolari di borse di studio di ricerca
Laura Labella Studentessa Biotecnologie Mediche Medicina Sperimentale Altro personale aggregato Sapienza o esterni, titolari di borse di studio di ricerca
Daniela De Ieso Studentessa Biotecnologie Mediche Medicina Sperimentale Altro personale aggregato Sapienza o esterni, titolari di borse di studio di ricerca
Giovanna Blaconà Dottoranda Medicina Sperimentale Altro personale aggregato Sapienza o esterni, titolari di borse di studio di ricerca
Abstract

The aim of this proposal is to clarify the molecular mechanisms of a gene targeting approach called Small Fragment Homologous Replacement (SFHR). This approach can stably modify a genomic sequence by homologous replacement of a small DNA fragment and could correct mutations within disease genes. SFHR mechanism is poorly understood and its practical application is limited by a low and variable frequency of correction.
We already published experimental evidences about the interconnection between SFHR, DNA methylation, chromatin remodelling, DNA repair and cell cycle pathways. We also published a selection of 18 specific genes within DNA repair and cell cycle pathways involved in the SFHR. Both the general pathways and the related specific genes are excellent targets for SFHR molecular mechanism study and manipulation.
This proposal will focus on the relationship between the 4 pathways listed above and SFHR, with particular regard to the enhancing of correction efficiency. This relationship will be studied in human Cystic Fibrosis (CF) cells of airway epithelium. Both primary differentiated and long-term stem-induced (by the culture reprogramming condition - CRC - approach) CF airway epithelial cells will be used. Drugs acting on each of the 4 pathways and single gene targeting will be used to dissect the pathways and to manipulate SFHR efficiency. A possible enhancement of SFHR by the use of CRISPR/Cas9 method will also be evaluated.
These studies will contribute to a better comprehension of the molecular mechanisms of homologous genomic replacement after the uptake and intracellular processing of exogenous DNA. The selection of molecular targets to manipulate will provide suggestions for increasing gene repair efficiency. The application to both differentiated and stem-induced cells may highlight new perspective for SFHR therapeutic applications, in particular to CF.

ERC
LS2_1, LS3_12, LS2_5
Keywords:
TERAPIA GENICA, EPIGENETICA E REGOLAZIONE GENICA, CICLO CELLULARE E DIVISIONE CELLULARE, GENETICA MOLECOLARE, BIOLOGIA DELLE CELLULE STAMINALI

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma